Dx Test Developers Experience Declining Revenue Growth

The news this week that CMS may reduce rates for some molecular diagnostic tests (by over 70% in a couple of cases) stimulated the idea of taking a quick look at the current market dynamics for diagnostic test developers. For this week’s post we decided to...

CROs Identifying Business Opportunities with Biomarkers

We are interested in how biomarkers are used in all aspects of healthcare.  Today Amplion is focused on the supporting the research side of healthcare with our product BiomarkerBase, helping diagnostic, pharma and life science companies make strategic decisions...

Is This a Big Opportunity for Diagnostic Test Developers?

Since the inception of this blog over 4 years ago, one of the key topics has been companion diagnostic testing for cytochrome p450 (CYP) mutations. Indeed this was the topic of the very first post. Testing for these mutations is increasing rapidly, but CYPs remain in...

CMS Plan for Test Pricing Seems to Favor Large Labs

CMS has finally released its plan for market-based reimbursement of lab testing, and early reaction from industry seems to be that large test providers such as Quest and LabCorp will benefit most from the new system. The new system requires that “applicable...

Why Personalized Medicine Matters

President Obama is pushing the term “Precision Medicine.” I was already pretty comfortable with the existing name for the movement, “Personalized Medicine,” but for a brief time bought into using the President’s term instead. Precision Medicine does...